Premium
Effect of benzopyranoperidine, a Δ‐9‐THC congener, on pain
Author(s) -
Jochimsen Peter R.,
Lawton Richard L.,
VerSteeg Kyle,
Noyes Russell
Publication year - 1978
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1978242223
Subject(s) - congener , chemistry , environmental chemistry
In a double‐blind, 5‐way crossover designed study, single doses of placebo, 2 doses of codeine sulfate (60 and 120 mg), and 2 doses of benzopyranoperidine (2 and 4 mg) were administered orally to 35 patients who required analgesics for chronic pain due to malignancies. Benropyranopyridine is an analogue of delta‐9‐tetrahydrocannabinol and was chosen on the basis of its sedative, hypnotic, and analgesic properties in animals. Pain relief scores indicated a degree of relief of clinical significance witn 120 mg of codeine but no consistent difference between placebo and any other active agent. On the basis of the data, benzopvranoperidine (2 or 4 mg) is not as effective as codeine (120 mg or 60 mg) and no more effective than placebo in relieving pain due to cancer; indeed, pain perception appeared to be augmented by both doses.